Fund HoldingsCAXTON CORP

Total Portfolio Value
$4.28M
Total Bought
$415.5K
Total Sold
$19.50M
Net Transaction
-$19.09M
Filing Period:
Securities
SharesValue ($K)
Q3 2025
Q4 2025
Change
Q3 2025
Q4 2025
Weight (%)
Change
SPYRE THERAPEUTICS INC(SYRE)08,919+8,91902926.83%+292
SPDR GOLD TR(GLD)7,2866,964-3222,5902,76064.50%+170
X4 PHARMACEUTICALS INC015,557+15,5570621.45%+62
KYVERNA THERAPEUTICS INC22,98118,773-4,2081381764.12%+39
INHIBIKASE THERAPEUTICS INC16,39328,453+12,06027581.36%+32
BERKSHIRE HATHAWAY INC DEL651710+593273578.34%+29
LEXEO THERAPEUTICS INC17,33213,943-3,3891151383.24%+23
SAB BIOTHERAPEUTICS INC10,93510,527-40822390.92%+17
CONTEXT THERAPEUTICS INC18,40318,403018270.63%+9
COMPASS THERAPEUTICS INC53,50329,495-24,0081871583.70%-29
MIND MEDICINE MINDMED INC27,01115,688-11,3233182104.91%-108
BICARA THERAPEUTICS INC10,9410-10,9411730-173
ENLIVEN THERAPEUTICS INC13,0970-13,0972680-268
REZOLUTE INC1,986,8180-1,986,81818,6760-18,676
Page 1 of 1